Souhaitez-vous accéder aux communiqués récents ?

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support the start of a Phase 1b clinical trial in rheumatoid...

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support the start of a Phase 1b clinical trial in rheumatoid...

Exton, PA, May 28, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the 2026 update of Market Dynamix™: Idiopathic Inflammatory Myopathies (IIM), US, revealing a market increasingly...

Autolus Therapeutics announced its operational and financial results for the first quarter ended March 31, 2026.

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "IgG4-Related Disease Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

Dublin, April 22, 2026 (GLOBE NEWSWIRE) -- The "Sjogren's Syndrome Market - A Global and Regional Analysis: Focus on Symptoms, Type, Route of Administration, End Users, and Region, 2025-2035" report...

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials

Boehringer and Sitryx Therapeutics partner to advance autoimmune and inflammatory disease research for more personalized, targeted, data driven treatment.

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...